#Zolgensma #Zolgensma #Zolgensma

Zolgensma Approved!

AveXis, a Novartis company, has received FDA approval for Zolgensma.

Learn MoreLearn More

AveXis and Cure SMA to Co-Host Webinar on the FDA's Approval of Zolgensma

On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the

READ MORE

AveXis Issues Community Statement on Zolgensma Approval

AveXis Issues Community Statement on Zolgensma Approval

Dear SMA Community,

We have exciting news to share with you — a major milestone has been reached in the fight against spinal...

READ MORE

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

AveXis, Inc., a Novartis company, today...

READ MORE

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

Audrey Lewis founded Families of SMA, now Cure SMA, 34 years ago. Audrey recognized early on the importance of attracting new and talented...

READ MORE

Cure SMA Attends the 71st Annual American Academy of Neurology (AAN) Meeting in Philadelphia

The American Academy of Neurology (AAN) 2019 Annual meeting wrapped up in Philadelphia, Pennsylvania on May 10th, 2019. The AAN Annual meeting...

READ MORE

© 2019 Cure SMA | Cure SMA is recognized as tax-exempt under section 501(c)(3) of the Internal Revenue Code. EIN: 36-3320440. | Privacy Policy

Powered by Blackbaud
nonprofit software